Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice.
Qingjuan ZuoGuorui ZhangLili HeSai MaHuijuan MaJianlong ZhaiZhongli WangTingting ZhangYan WangYifang GuoPublished in: Drug design, development and therapy (2022)
Canagliflozin may attenuate hepatic steatosis by improving lipid metabolism, enhancing autophagy, and reducing inflammatory response through ASS1/AMPK pathway. Besides, canagliflozin further effectively improves the aortic endothelial function, thereby suppressing atherosclerosis development.
Keyphrases
- inflammatory response
- cardiovascular disease
- signaling pathway
- cell death
- physical activity
- aortic valve
- lipopolysaccharide induced
- endoplasmic reticulum stress
- oxidative stress
- cognitive decline
- south africa
- skeletal muscle
- weight loss
- high fat diet
- pulmonary artery
- fatty acid
- heart failure
- immune response
- metabolic syndrome
- adipose tissue
- insulin resistance
- protein kinase
- aortic dissection